Rel-A/PACER/miR 7 Axis May Play a Role in Radiotherapy Treatment in Breast Cancer Patients
Breast cancer
, Radiation biomarkers
Radiotherapy
Journal
Iranian biomedical journal
ISSN: 2008-823X
Titre abrégé: Iran Biomed J
Pays: Iran
ID NLM: 9814853
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
aheadofprint:
08
05
2023
medline:
29
8
2023
pubmed:
29
7
2023
entrez:
28
7
2023
Statut:
epublish
Résumé
Radiotherapy has become the standard form of treatment for breast cancer (BC). Radioresistance is an issue that limits the effectiveness of radiotherapy (RT). Therefore, predictive biomarkers are needed to choose the appropriate RT for the patient. Activation of the proinflammatory transcription factor, nuclear factor-kappa B (NF-κB), is a frequently noted pathway in BC. Investigating the relationship between RT and alterations in gene expression involved in the immune pathway can help better control the disease. This research investigated the impact of RT on the expression levels of Rel-A, PACER, and miR-7 within the NF-κB signaling pathway. Blood samples (n = 15) were obtained from BC patients during four different time intervals: 72 hours prior to initiating RT, as well as one, two, and four weeks following RT completion. Samples were also collected from 20 healthy women who had no immune or cancer-related diseases. Blood RNA was extracted, and complementary DNA was synthesized. Gene expression level was determined using R real-time polymerase chain reaction (RT-PCR). There was a significant difference in the expression level of Rel-A between patients and normal individual blood samples (p < 0.05). After four weeks of RT, qRT-PCR revealed a significant downregulation of miR-7 and upregulation of Rel-A and PACER in BC patients. Also, there was a significant association between Rel-A expression and monocyte numbers during RT (p < 0.001). The expression level of PACER, miR-7 and Rel-A, changed after RT; therefore, these genes could be used as diagnostic and therapeutic RT markers in BC.
Sections du résumé
Background
Radiotherapy has become the standard form of treatment for breast cancer (BC). Radioresistance is an issue that limits the effectiveness of radiotherapy (RT). Therefore, predictive biomarkers are needed to choose the appropriate RT for the patient. Activation of the proinflammatory transcription factor, nuclear factor-kappa B (NF-κB), is a frequently noted pathway in BC. Investigating the relationship between RT and alterations in gene expression involved in the immune pathway can help better control the disease. This research investigated the impact of RT on the expression levels of Rel-A, PACER, and miR-7 within the NF-κB signaling pathway.
Methods
Blood samples (n = 15) were obtained from BC patients during four different time intervals: 72 hours prior to initiating RT, as well as one, two, and four weeks following RT completion. Samples were also collected from 20 healthy women who had no immune or cancer-related diseases. Blood RNA was extracted, and complementary DNA was synthesized. Gene expression level was determined using R real-time polymerase chain reaction (RT-PCR).
Results
There was a significant difference in the expression level of Rel-A between patients and normal individual blood samples (p < 0.05). After four weeks of RT, qRT-PCR revealed a significant downregulation of miR-7 and upregulation of Rel-A and PACER in BC patients. Also, there was a significant association between Rel-A expression and monocyte numbers during RT (p < 0.001).
Conclusion
The expression level of PACER, miR-7 and Rel-A, changed after RT; therefore, these genes could be used as diagnostic and therapeutic RT markers in BC.
Identifiants
pubmed: 37507347
doi: 10.52547/ibj.3901
pmc: PMC10507291
doi:
Substances chimiques
NF-kappa B
0
MicroRNAs
0
MIRN7 microRNA, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-82Références
Elife. 2014 Apr 29;3:e01776
pubmed: 24843008
J Clin Invest. 2004 Aug;114(4):569-81
pubmed: 15314694
J Fac Radiol. 1959 Jul;10:130-3
pubmed: 24546197
Toxicol Lett. 2011 Sep 10;205(3):320-6
pubmed: 21726609
Radiother Oncol. 2011 Oct;101(1):171-6
pubmed: 21676478
Mol Ther Oncolytics. 2020 Jun 04;18:70-82
pubmed: 32637582
Cancer Res. 2007 Apr 1;67(7):3220-8
pubmed: 17409430
Nat Rev Mol Cell Biol. 2004 May;5(5):392-401
pubmed: 15122352
Cancer Lett. 2004 Apr 8;206(2):193-9
pubmed: 15013524
PLoS One. 2011;6(11):e27722
pubmed: 22110741
Trends Mol Med. 2002 Aug;8(8):385-9
pubmed: 12127724
Nature. 2001 Nov 15;414(6861):313-7
pubmed: 11713531
Free Radic Biol Med. 2008 Jan 1;44(1):1-13
pubmed: 17967430
Recent Results Cancer Res. 1988;111:108-29
pubmed: 2856863
PLoS One. 2013 May 28;8(5):e65153
pubmed: 23724129
Stem Cells. 2014 Nov;32(11):2858-68
pubmed: 25070049
Mol Cancer Res. 2006 Apr;4(4):221-33
pubmed: 16603636
Br J Cancer. 2007 Sep 3;97(5):659-69
pubmed: 17700572
J Pathol. 2014 Mar;232(4):415-27
pubmed: 24293274
Oncogene. 2004 Jan 15;23(2):535-45
pubmed: 14724581
Cancer Cell. 2004 Sep;6(3):203-8
pubmed: 15380510
Biochim Biophys Acta. 2006 Aug;1766(1):53-62
pubmed: 16563635
Curr Mol Med. 2006 Aug;6(5):515-24
pubmed: 16918372
Mol Cell Biol. 2003 Apr;23(7):2362-78
pubmed: 12640121
Cancer Res. 2004 Sep 1;64(17):6240-6
pubmed: 15342410
Nat Rev Cancer. 2002 Apr;2(4):301-10
pubmed: 12001991
Anticancer Res. 2006 Nov-Dec;26(6B):4235-43
pubmed: 17201139
Breast Cancer Res. 2011 Jul 26;13(4):214
pubmed: 21867572
Discoveries (Craiova). 2015 Mar 31;3(1):e35
pubmed: 32309561
Cancer Lett. 2015 Mar 1;358(1):27-36
pubmed: 25511742
Cancer Biol Ther. 2003 Jul-Aug;2(4):326-9
pubmed: 14508100
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Arch Toxicol. 2015 May;89(5):711-31
pubmed: 25690730
J Mammary Gland Biol Neoplasia. 2003 Apr;8(2):215-23
pubmed: 14635796
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13021-6
pubmed: 18755890
Mol Med Rep. 2015 Nov;12(5):7396-402
pubmed: 26458302
Cancer Res. 2002 Feb 15;62(4):1213-21
pubmed: 11861406
Signal Transduct Target Ther. 2020 Sep 21;5(1):209
pubmed: 32958760
Lancet. 1974 Nov 30;2(7892):1285-6
pubmed: 4139524
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878